Clin Microbiol Infect 2012; 18: 997–1003 Abstract In recent years, we have successfully established a novel method of haploidentical haematopoietic stem cell transplantation (HSCT) without in vitro T‐cell depletion. This study was aimed at analysing the incidence and risk factors of invasive fungal infection (IFI) with this transplantation method. The study comprised 291 patients who had undergone haploidentical HSCT from 1 January 2007 to 31 December 2008. IFI was diagnosed according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group 2002 criteria, and only proven or probable cases of IFI were regarded as true cases. A total of 39 patients were documented as having IFI, including four proven cases and 35 probable cases. The median time of diagnosis was 26 days (range: 6–405 days) after transplantation. The cumulative incidence rates of IFI at 40 days, 1 year, 2 years and 3 years after transplantation were 8.25%, 13.1%, 13.4% and 13.4%, respectively. Multivariate analysis identified platelet engraftment time (>17 days) (p 0.027; hazard ratio (HR) 2.432; 95% CI 1.105–5.355), a high risk of underlying disease (p 0.001; HR 2.916; 95% CI 1.515–5.611) and grade III–IV acute graft‐versus‐host disease (p 0.019; HR 2.407; 95% CI 1.154–5.022) as risk factors for IFI. The incidence rates of IFI in patients with no, one, two or three risk factors at 3 years after transplantation were 4.48%, 7.86%, 29.6% and 23.1%, respectively. In conclusion, IFI is an important complication following haploidentical HSCT without in vitro T‐cell depletion.

Cytomegalovirus (CMV) infection and delayed immune reconstitution remains a serious obstacle for successful partially matched-related donor transplantation (PMRD). We evaluated 42 patients for the development of CMV-specific CD8+ T lymphocytes (CTL(CMV) ) following granulocyte colony-stimulating factor-primed peripheral blood (PB) and bone marrow (BM) with anti-thymocyte globulin (ATG)-based PMRD. PMRD recipients achieved a high frequency, proliferation capacity, and interferon-γ response of CTL(CMV) at 1 year post transplantation. CTL(CMV) with the central memory CD45RO+CD62L+ cell phenotype expanded in PB and BM-resident CTL(CMV) displayed distinct phenotypes when CMV was reactivated. Although the incidence of CMV reactivation was high in PMRD patients (87.67%), only 11.90% of them developed CMV disease. In conclusion, after PMRD using mixed grafts with ATG-based conditioning, immune recovery to CMV seems to be early and fast, thereby reducing the incidence of CMV disease.

No abstract

No abstract